Top Back to top

High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis

Autoimmune Diseases Working Party (ADWP)
Study number:
2006-004598-83
Type of transplant:
 
Short title:
ASTIS
Study status:
Completed Patient Recruitment
Deadline for data collection:
 
Study design:
Multicentre, randomised, controlled trial
Primary objective:
To evaluyate the potential clinical benefit of high dose immunoablation and autologous stem cell transplantation in comparison to intravenous pulse therapy cyclophosphamide, with respect to survival and prevention of major organ failure, safety, impact on skin thickening, visceral involvement, functional status and quality of life.
Key inclusion criteria:
18-65 years
Country:
Austria
Belgium
Canada
France
Germany
Greece
Italy
Netherlands
Switzerland
United Kingdom
Principal investigator:
J.M. van Laar
Principal investigator email:
 
EBMT Study coordinator:
Ruzena Uddin